~~<i id='09325726CA'><strike id='09325726CA'><tt id='09325726CA'><pre id='09325726CA'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：leisure time 2025-10-04 11:32:21 Page View：515

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Failure, not just success, should guide future doctors
Next article： Novavax promises a turnaround & Lilly roils the obesity market

explore

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Amylyx ALS drug fails large clinical trial

JustinKlee(left)andJoshuaCohenaretheco-foundersandco-CEOsofAmylyxPharmaceuticals.KayanaSzymczakforST

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

1:12AsummerderechoblowspasttheCapitolinWashington,DC,Aug.7,2023.Forthefirsttimeinmorethan10years,the

WSS

comprehensive

comprehensive

knowledge

explore

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast